In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Research UK’s CRT: A Bridge Between Big Pharma And Academia

Executive Summary

Britain’s Cancer Research Technology says the dire financing situation facing European biotechs has forced it to become a bridge builder between research-based Big Pharma and academia, an intermediary role that it expects to expand on as the search for new oncology drugs intensifies.

You may also be interested in...



AstraZeneca, Pfizer, U.K. Charity’s Joint Lung Cancer Trial Aims To Make Tumor Genetic Testing Routine

A pioneering approach to trialing targeted medicines in late-stage NSCLC is being launched throughout Britain, giving researchers unprecedented access to libraries of drugs developed by AstraZeneca and Pfizer, allowing several to be tested at the same time within one trial.

Teva, CRT Build On Tie That Produced aPKC Protein Inhibitor Candidate

By jointly finding a first-in-class atypical Protein Kinase C inhibitor preclinical candidate, Israel’s Teva and Britain’s Cancer Research Technology have successfully capped a four-year collaboration and are now branching out into the area of DNA damage response.

AZ’s MedImmune Buys Spirogen To Boost Oncology ADC Capability

AstraZeneca agreed to pay $200 million upfront and $240 million in predefined milestones for Spirogen to enhance its early oncology pipeline with linked tumor-targeted antibody drug conjugates. The company simultaneously announced a collaboration with ADC Therapeutics to jointly develop ADCs.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel